1 Role of Artificial Intelligence-Powered Conversational Agents (Chatbots) in 2 **Musculoskeletal Disorders: A Scoping Review Protocol** 3 4 Joaquín González Aroca<sup>\* 1</sup>, Laura Vergara-Merino <sup>2</sup>, Camila Micaela Escobar Liquitay <sup>3</sup> Humberto Farías A<sup>4</sup>, Jorge Olivares Arancibia <sup>5</sup> and Álvaro Puelles <sup>1</sup> 5 6 7 1 School of Kinesiology, Universidad de La Serena, La Serena, Chile 8 2 Department of Traumatology and Orthopedics, Pontificia Universidad Católica de Chile, 9 Chile. 10 3 Research Department, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos 11 Aires, Argentina 12 4 Department of Industrial Engineering, Universidad de La Serena, La Serena, Chile 5 AFySE Group, Research in Physical Activity and School Health, School of Pedagogy in 13 14 Physical Education, Faculty of Education, Universidad de las Américas, Santiago, Chile. 15 \* Correspondence: joaquin.gonzalez@userena.cl 16 17 Word count: 1103 18 19 Keywords: Musculoskeletal Disorders; Artificial intelligence; Chatbot 20 21 Abstract 22 Introduction: Musculoskeletal disorders (MSDs) represent a significant global health 23 burden, leading to substantial disability and socioeconomic impact. With the rise of artificial intelligence (AI), particularly large language models-driven conversational agents 24 25 (chatbots), there is potential to enhance the management of MSDs. However, the 26 application of AI-powered chatbots in this population has not been comprehensively 27 synthesized. 28 29 **Objective**: To explore the current and potential use of AI-powered chatbots in the 30 management of MSDs. The review will map out the targeted diseases, the purposes of 31 chatbot interventions, the clinical tools or frameworks utilized in training these systems, 32 and the evaluated outcomes in clinical settings. 33 34 **Methods**: This scoping review will follow the PRISMA-ScR guidelines, with a comprehensive 35 search across multiple databases including Medline (Ovid MEDLINE), Embase (Ovid), ISI Web of Science (wos; clarivate) and ClinicalTrials.gov. Studies involving adults with MSDs, 36

37 regardless of publication status, language, or year, will be included. The scoping review will
38 exclude studies using non-AI chatbots or human health coaches. Data extraction and
39 synthesis will focus on demographic characteristics, chatbot methods, outcomes, and
40 thematic analysis.

41

42 **Ethics and dissemination**: Formal ethical approval is not required as this study involves 43 neither human participants nor unpublished secondary data. Findings of the scoping review will be disseminated through professional networks, conference presentations andpublication in a scientific journal.

46

# 47 Strengths and limitations of this study

- 48
- 49 50
- We developed a search strategy with high sensitivity to retrieve studies
- This scoping review will not exclude studies by publication status, language, or year of publication.

## 53 Introduction

54

51

52

55 Musculoskeletal disorders (MSDs) are a significant global health concern, ranking as the second cause of non-fatal disability in 2020 and affecting over 1.63 billion individuals 56 57 worldwide.<sup>1</sup> The burden of MSDs extends beyond physical limitations, often leading to 58 substantial disability, with MSDs topping the list in terms of years lost to disability, according to the latest Global Burden of Disease report.<sup>2</sup> The enduring pain and disability associated 59 60 with MSDs can also precipitate long-term psychological consequences.<sup>3</sup> Additionally, the considerable healthcare costs and the strain on workforce availability further compound 61 62 the societal burden of these conditions.<sup>4</sup>

63

64 Amidst these challenges, artificial intelligence (AI) emerges as a transformative tool, 65 reshaping how we process information and augmenting decision-making processes through 66 problem-solving, reasoning, and learning. AI encompasses a range of methods, including machine learning, deep learning (DL), and natural language processing (NLP). Large 67 Language Models (LLMs) represent a specific type of AI that employs DL and extensive 68 69 datasets to comprehend, summarize, generate, and forecast new text-based content <sup>5-7</sup>. In the healthcare field, AI applications are diverse, ranging from machine learning algorithms 70 that assist in diagnostic tools to LLMs that dialogue with patients. <sup>8</sup> This ability to engage in 71 72 real-time dialogue with patients not only improves accessibility to healthcare services but 73 also empowers patients by offering immediate, reliable information. Particularly, NLP 74 models based on LLMs have gained prominence, enhancing their capabilities by generating 75 and understanding human language through learned patterns rather than relying solely on predefined rules.<sup>9-10</sup> From these models, the use of Chatbots arise These systems engage 76 77 users in dialogue, -typically online- and generate responses based on analyzed inputs and 78 accessed knowledge.<sup>11</sup>

79

The use of chatbots has been reported in various aspects of health care, such as cancer <sup>12</sup>, behavioral change <sup>13</sup>, and psychiatry <sup>14</sup>, among others. Particularly in musculoskeletal care, chatbots have been studied in people with chronic pain <sup>15</sup>, shoulder arthroplasty <sup>16</sup>, and back pain <sup>17</sup>. However, to our knowledge, there is no evidence synthesis about the use of chatbots in this population.

85

86 This scoping review aims to provide an overview of the current and potential use of Artificial

87 Intelligence-Powered Conversational Agents (chatbots) in people with MSD.

00				
88				
89	Review questions			
90	1. In the context of MSDs, in which diseases and for what purpose have chatbots been			
91	used? (eg. medication reminders, exercise-based treatments reminders, education			
92	and motivation)			
93	2. What clinical tools or conceptual frameworks are serving as benchmarks in training			
94	chatbots with artificial intelligence algorithms for application in clinical settings			
95	related to musculoskeletal conditions?			
96	3. What outcomes are evaluated when implementing AI chatbots for the management			
97	of musculoskeletal disorders in clinical settings?			
98				
99	Methods and analysis			
100				
101	This scoping review will be developed following the Preferred Reporting Items for			
102	Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). <sup>18</sup>			
103				
104	Eligibility Criteria			
105				
106	This review will include all primary studies that assess the use of AI chatbots in adults (older			
107	than 18 years) with a musculoskeletal disease in any setting. Musculoskeletal disorders			
108	refer to a diverse set of conditions affecting muscles, bones, joints, and related tissues, with			
109	symptoms that can vary in duration.			
110	Articles will be excluded if they (1) used chatbots that did not incorporate AI (eg, chatbots			
111	and computerized coaches that were not conversational and without machine learning			
112	capabilities), (2) used human health coaches conversing with users through messaging			
113	platforms and (3) included participants that experience pain due to particular pathological			
114	causes (such as neurological disease, malignancy, inflammatory disease) will be excluded.			
115				
116	We will not exclude by status of publication, language, or year of publication.			
117	we will not exclude by status of publication, language, or year of publication.			
118	Narrative reviews, letters to editors, or any non-original study will be excluded from this			
119	scoping review.			
120	scoping review.			
120	Search Methods			
121	Search Methous			
122	We will search the following databases from inception with no restrictions on date,			
124	language or publication status:			
125				
126	1. Medline (Ovid MEDLINE);			
127	2. Embase (Ovid);			
128	3. ISI Web of Science (wos; clarivate);			
129	4. ClinicalTrials.gov ( <u>www.clinicaltrials.gov</u> );			
130	For detailed search strategies, see <b>Appendix 1</b>			
131				

#### 132 Selection of studies

133

All identified records will be uploaded to the Rayyan web application after duplicates 134 removal. Prior to the screening process, a pilot test of the proposed eligibility criteria will 135 136 be performed using three to ten articles to solve any possible disagreements regarding the 137 selection process. Two independent reviewers will then screen titles and abstracts, and further select the studies by reading the full text of potentially eligible studies. If there is a 138 139 discrepancy in any step of the selection process a third reviewer will decide whether the study meets the eligibility criteria. The search results and the reasons for exclusions will be 140 141 recorded and reported in a PRISMA-ScR flowchart.

142

#### 143 Data extraction process

144

Two independent reviewers will extract data from the selected articles into a predefined template. For each study we will extract the Author, year of publication, country of origin, objectives, study population and sample size, intervention or exposure, measured outcomes, details of these outcomes, musculoskeletal disorder, and those key findings that relate to the question of this review. In case of discrepancies, a third reviewer will participate in this process.

- 151
- 152

### 52 Collating, summarising and reporting the results

153

154 The findings will be summarized in accordance with PRISMA-ScR guidelines, focusing on descriptive and thematic analysis. Descriptive elements will cover demographic 155 156 characteristics, research country, publication details, and bibliometric data. This includes 157 musculoskeletal diagnosis, description of the AI chatbot method, purpose of the AI chatbot, nature of the dataset (eg, size, data cleaning or preparation methods), the outcomes 158 assessed, knowledge user engagement and healthcare setting of the study. Additionally, we 159 160 may conduct further bibliometric analysis, such as cocitation networks among authors and countries using VosViewer.<sup>19</sup> Furthermore, a thematic summary will be provided to 161 162 emphasize the main themes identified in the literature.

163

### 164 **Ethics and dissemination**

165

Formal ethical approval is not required as this study involves neither human participants nor unpublished secondary data. Findings of the scoping review will be disseminated through professional networks, conference presentations and publication in a scientific journal.

170

### 171 Patient and public involvement

172 The design of this scoping review protocol did not involve patients. However, patients'

- beliefs and experiences are central to the research question
- 174

175			
176	References		
177			
178	1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global,		
179	regional, and national incidence, prevalence, and years lived with disability for 354		
180	diseases and injuries for 195 countries and territories, 1990-2017: a systematic		
181	analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov		
182	10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.		
183	Erratum in: Lancet. 2019 Jun 22;393(10190):e44. doi: 10.1016/S0140-		
184	6736(19)31047-5.		
185	2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and		
186	injuries in 204 countries and territories, 1990-2019: a systematic analysis for the		
187	Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222.		
188	doi: 10.1016/S0140-6736(20)30925-9. Erratum in: Lancet. 2020 Nov		
189	14;396(10262):1562. doi: 10.1016/S0140-6736(20)32226-1.		
190	3. Björnsdóttir SV, Jónsson SH, Valdimarsdóttir UA. Mental health indicators and		
191	quality of life among individuals with musculoskeletal chronic pain: a nationwide		
192	study in Iceland. Scand J Rheumatol. 2014;43(5):419-23. doi:		
193	10.3109/03009742.2014.881549.		
194	4. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012		
195	Aug;13(8):715-24. doi: 10.1016/j.jpain.2012.03.009.		
196	5. Suleimenov IE, Vitulyova YS, Bakirov AS, Gabrielyan OA. Artificial Intelligence:what		
197	is it? Proc 2020 6th Int Conf Comput Technol Appl. 2020;22–5.		
198	https://doi.org/10.1145/3397125.3397141.		
199	6. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. Future		
200	Healthc J. 2019 Jun;6(2):94-98. doi: 10.7861/futurehosp.6-2-94.		
201	7. Russell SJ. Artificial intelligence a modern approach. Pearson Education, Inc.; 2010.		
202	8. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN,		
203	Aldairem A, Alrashed M, Bin Saleh K, Badreldin HA, Al Yami MS, Al Harbi S, Albekairy		
204	AM. Revolutionizing healthcare: the role of artificial intelligence in clinical practice.		
205	BMC Med Educ. 2023 Sep 22;23(1):689. doi: 10.1186/s12909-023-04698-z. PMID:		
206	37740191; PMCID: PMC10517477.		
207	9. Fralick M, Sacks CA, Muller D, Vining T, Ling E, Drazen JM, Hardin CC. Large Language		
208	Models. NEJM Evid. 2023 Aug;2(8):EVIDstat2300128. doi: 10.1056/EVIDstat2300128.		
209	•		
210 211	10. Thirunavukarasu AJ, Ting DSJ, Elangovan K, Gutierrez L, Tan TF, Ting DSW. Large language models in medicine. Nat Med. 2023 Aug;29(8):1930-1940. doi:		
211	10.1038/s41591-023-02448-8.		
212	11. Dahiya M. A tool of conversation: chatbot. Int J Comput Sci Eng. 2017 May		
213	30;5(5):158		
214	12. Xu L, Sanders L, Li K, Chow JCL. Chatbot for Health Care and Oncology Applications		
215	Using Artificial Intelligence and Machine Learning: Systematic Review. JMIR Cancer.		
210	2021 Nov 29;7(4):e27850. doi: 10.2196/27850.		
/			

- Aggarwal A, Tam CC, Wu D, Li X, Qiao S. Artificial Intelligence-Based Chatbots for
   Promoting Health Behavioral Changes: Systematic Review. J Med Internet Res. 2023
   Feb 24;25:e40789. doi: 10.2196/40789.
- 14. Gallegos C, Kausler R, Alderden J, Davis M, Wang L. Can Artificial Intelligence
   Chatbots Improve Mental Health?: A Scoping Review. Comput Inform Nurs. 2024 Jun
   27. doi: 10.1097/CIN.00000000001155.
- 15. Andrews NE, Ireland D, Vijayakumar P, Burvill L, Hay E, Westerman D, Rose T,
  Schlumpf M, Strong J, Claus A. Acceptability of a Pain History Assessment and
  Education Chatbot (Dolores) Across Age Groups in Populations With Chronic Pain:
  Development and Pilot Testing. JMIR Form Res. 2023 Oct 6;7:e47267. doi:
  10.2196/47267.
- 16. Blasco JM, Navarro-Bosch M, Aroca-Navarro JE, Hernández-Guillén D, PuigcerverAranda P, Roig-Casasús S. A Virtual Assistant to Guide Early Postoperative
  Rehabilitation after Reverse Shoulder Arthroplasty: A Pilot Randomized Trial.
  Bioengineering (Basel). 2024 Feb 2;11(2):152. doi:
  10.3390/bioengineering11020152.
- 17. Anan T, Kajiki S, Oka H, Fujii T, Kawamata K, Mori K, Matsudaira K. Effects of an
  Artificial Intelligence-Assisted Health Program on Workers With Neck/Shoulder
  Pain/Stiffness and Low Back Pain: Randomized Controlled Trial. JMIR Mhealth
  Uhealth. 2021 Sep 24;9(9):e27535. doi: 10.2196/27535.
- 18. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ,
  Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L,
  Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV,
  Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for
  Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018
  Oct 2;169(7):467-473. doi: 10.7326/M18-0850.
- 19. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for
  bibliometric mapping. Scientometrics. 2010 Aug;84(2):523-538. doi:
  10.1007/s11192-009-0146-3.
- 247 248

Authors' contributions: JGA descent conceived the idea of this project, established the research question and methodology, and led the development of the protocol. LV and HF contributed to the methods and gave meaningful contributions to the development and/or editing of the protocol. CMEL and JGA developed the search strategies. JOA and AP helped refine the protocol. All authors have approved the final version of the protocol.

- 254
- Funding statement: This research received no specific grant from any funding agency in thepublic, commercial or not-for-profit sectors.
- 257

258 **Competing interests statement**: The authors have no conflicts of interest to declare.

259

260 261	Appendix 1			
261	Medline (Ovid)			
263				
264	Ovid MEDLINE(R) ALL / PubMed(R) <1946 to Present>			
265				
266	1	"artificial intelligence".ti,ab. or exp Artificial Intelligence/ 226908		
267	2	Chatbot*.ti,ab. 1841		
268	3	Musculoskeletal Diseases/ 15920		
269	4	(bone or Orthopedic or Coxa or Osteochondritis or Hip or Knee or Ankle or Shoulder		
270	or wrist or Hand or Spine or Back or Neck or Arthritis or limb or orthop* or osteochondr* or			
271	Osteonecros* or osteoporos* or periarthriti* or polymyalgia* or scleroderma* or			
272	Spondylarthrit* or sprain or fracture* or sciatica).ti,ab. 2770180			
273	5	3 or 4 2778974		
274	6	1 or 2 227817		
275	7	animals/ not humans/ 5218162		
276	8	5 and 620840		
277	9	8 not 7. 3565		
278				
279				